best nasdaqs stocks

Leaves out of trouble but loses independence: Meilan merges pharmaceutical activity without a patent with Pfizer

Within the framework of the move, the controlling interest (60%) in Meilan will be transferred to Pfizer shareholders, while the shareholders of Meilan will waive 40% of the merged companyThe generic drug company Meilan is in negotiations to merge Pfizer’s non-patented pharmaceutical operations, in which 60% of the company will be transferred to Pfizer shareholders, while Mellan’s shareholders will leave 40% of the merged company. Meilan Chief Executive Officer Heather Barash and President Rajiv Malik. Milen’s legendary chairman Robert Corrie will be chairman of the new Meilan, which will be run by Pfizer CEO Michael Gutler.hese were published in the Wall Street Journal and have not yet been verified by the companies, but have been verified by other media outlets from abroad.Among the drugs that may be passed on to Mielan in the course of the process are Lipitor’s best-selling drugs for lowering cholesterol and Viagra for the treatment of male impotence.Non-patent drugs have a significantly lower profit than new drugs, so businesses are completely different in character than drugs that still have a patent. Pfizer concentrates most of its efforts on patented drugs, while those without patents remain behind. In contrast, Meilan is engaged in generic drugs, mimicking new drugs when their patent expires. Its business is much more like that of the pharmaceutical division without Pfizer’s patent than the new drug field, so the matchmaking makes sense.

Many large pharmaceutical companies today sell their non-patent drugs to other parties to concentrate on the innovative aspects of their pharmaceutical business. Except in the case of drugs without a patent of a very strong brand or unique ownership that have not yet been properly emulated.Presumably, some of Pfizer’s old drugs already have generic imitations created by Meilen, so this project may compete with Mailen’s own activity and some of the products may sell further so as not to create duplication. As part of the agreement, debt refinancing will also be carried out in both companies.Lost 75% of the peakMeilan is known to the Israeli investor as the generic drug company, which competes head to head in Teva over the years for the title of the world’s largest generics company. At the time of writing, Meilan is traded at a company value of $ 9.5 billion and has been valued at $ 8.5 billion, so that in terms of market value, the company is now the world’s largest independent generics company (both competing in India’s San Pharma) and Sandoz, Novartis’s generics division, Regardless, the Novartis general manager promised that he was not considering a similar sale or spin-off of the division.)

The American company, Meilan, was listed for trading in Tel Aviv in 2015 when it sought to acquire the American generic company Perrigo, which is also traded in Tel Aviv (after acquiring Agis in 2004). At the same time, Teva, traded at a higher value than Millen, wanted to buy it, an initiative that was met with a personal and insulting letter from Corey, chairman of Meilan, to Teva CEO Erez Vigodman, which made the business struggle very personal.Since then, both companies have been hit. Teva did not succeed in acquiring Meilan, and among other things, in order to leave with dignity from the move, acquired the allergen division and got into huge debts. Meilan did not buy Perrigo, but became the company in talks about the price of generic drugs for the 2016 US elections, and was forced to lower prices and its businesses were hurt.Leaves out of trouble but loses independence: Meilan merges pharmaceutical activity without a patent with Pfizer

Within the framework of the move, the controlling interest (60%) in Meilan will be transferred to Pfizer shareholders, while the shareholders of Meilan will waive 40% of the merged companyThe generic drug company Meilan is in negotiations to merge Pfizer’s non-patented pharmaceutical operations, in which 60% of the company will be transferred to Pfizer shareholders, while Mellan’s shareholders will leave 40% of the merged company. Meilan Chief Executive Officer Heather Barash and President Rajiv Malik. Milen’s legendary chairman Robert Corrie will be chairman of the new Meilan, which will be run by Pfizer CEO Michael Gutler.These were published in the Wall Street Journal and have not yet been verified by the companies, but have been verified by other media outlets from abroad.Among the drugs that may be passed on to Mielan in the course of the process are Lipitor’s best-selling drugs for lowering cholesterol and Viagra for the treatment of male impotence.Non-patent drugs have a significantly lower profit than new drugs, so businesses are completely different in character than drugs that still have a patent. Pfizer concentrates most of its efforts on patented drugs, while those without patents remain behind. In contrast, Meilan is engaged in generic drugs, mimicking new drugs when their patent expires. Its business is much more like that of the pharmaceutical division without Pfizer’s patent than the new drug field, so the matchmaking makes sense.

The American company, Meilan, was listed for trading in Tel Aviv in 2015 when it sought to acquire the American generic company Perrigo, which is also traded in Tel Aviv (after acquiring Agis in 2004). At the same time, Teva, traded at a higher value than Millen, wanted to buy it, an initiative that was met with a personal and insulting letter from Corey, chairman of Meilan, to Teva CEO Erez Vigodman, which made the business struggle very personal.Since then, both companies have been hit. Teva did not succeed in acquiring Meilan, and among other things, in order to leave with dignity from the move, acquired the allergen division and got into huge debts. Meilan did not buy Perrigo, but became the company in talks about the price of generic drugs for the 2016 US elections, and was forced to lower prices and its businesses were hurt.Since those peak days when each of the companies was the biggest trouble of the other, Teva lost 90% of its value. The Mayan share lost 75%.Now Mellan is out of trouble with the current merger that will turn it into a generic giant, but it will also lead it to lose its independence from the perspective of shareholders. From the point of view of the Milenian, Chairman Robert Corrie – he may still remain the strong man.

Pfizer continues to splitPfizer has been talking for several years about the option to split its pharmaceutical business and get rid of their share. A few years ago she had already issued her veterinary and agricultural business, which became Zoetis and helped Pfizer pay the debt it had at the time of the sale. In 2017, Pfizer began talking about spin-off to its over-the-counter drugs business (including patent-free drugs, but still leaving many prescription drugs without the parent’s patent, which will be combined with methylene). It is now preparing to merge this activity with GlaxoSmithKline (GSK).At the same time, Pfizer is also looking for a large acquisition, and in recent years it has tried to acquire AstraZeneca and Allergen, but the two giant deals have not been carried out.Now the market is waiting for the companies’ formal attention on Monday when the US work week opens.Significant acquisition of Ceva: “Hillcrest expands and redefines the boundaries of the technology solutions we offer, in a world where information is the driving force”According to estimates, Ceva paid tens of millions of dollars for Hillcrest, which supplies software and processing components integrated with electronics sensors and IoT

Technology company Ceva announced Monday its first significant acquisition after five years. At the same time, it is likely to benefit from another acquisition that is brewing between two giants. According to reports in The Wall Street Journal, Apple is in advanced negotiations for the acquisition of chip operations for smartphones modems from Intel, for which Ceva provides technology for this field.Ceva provides technologies for chip design for the cellular market and other markets. Hillcrest Labs, Inc. (NYSE: HL) today announced the acquisition of Hillcrest Labs’ fusion fusion sensors from the US by InterDigital, which provides software and processing components integrated with sensors for electronics and IoT products, and the company’s announcement has so far incorporated the technologies developed by Hillcrest in more than 100 million smart devices.(28.14 -2.97%)Did not report how much it paid for Hillcrest, but investment bank Roth Capital estimated it was a few dozen million dollars. Roth added that the acquisition will continue to diversify Ceva’s business and expand its operations in imaging and video. Roth’s recommendation for Ceva is a “buy” at a target price of $ 35, 36.8% higher than the current price on Nasdaq.

Seva is traded on Nasdaq at $ 562 million, after a 21% drop in its share price in the past year, and Ceva had $ 171 million at the end of the first quarter of 2006. Ceva’s previous major acquisition was RivieraWaves in 2014.Ceva noted that Hillcrest’s software can be integrated into the chips or end products themselves, and run the software on its signal processors as well as in various central processors. In this way, Siwa actually enters the CPU for the first time and reaches the final manufacturer of the device, and not just the chip manufacturer. This means that Siwa is expanding its royalty model and will be able to receive royalties from two different sources on each device sold and will include its own technology.This acquisition opens up opportunities for significant royalty growth, including final handset manufacturers, and also positions us as pioneers in the growing fields of rugged, virtual reality and robotics,” said Gideon Wertheiser, CEO of Ceva. In addition to our broad portfolio of technologies in the areas of connectivity, voice, image processing and artificial intelligence, Hillcrest’s addition expands and redefines the boundaries of the technological solutions we offer in a world where information is the driving force. “Ceva is waiting for Apple

Intel announced it was planning to move out of the fifth-generation mobile-chip business on the grounds of a compromise in a legal dispute between Apple and Qualcomm that ended with Apple announcing that it would acquire The company will be able to develop its own in-house components, and it is estimated that Ceva, whose technology is Part of it will be positively affected.A large deal in the kibbutz industry: Mishmar Ha’emek, where he is a foot in Evron’s water company, buys about a quarter of the shares at a company value of NIS 450 millionMishmar HaEmek is considered one of the richest kibbutzim and controls Tama Plastic Industries, considered one of the three leading and profitable companies in the kibbutz industry. In view of the large deal between two kibbutzim: Kibbutz Mishmar HaEmek Signed a memorandum of understanding several weeks ago to acquire 20% -25% of the private company in Ramad, from Kibbutz Evron and Saar at a company value estimated at NIS 450 million. The deal is expected to be closed after negotiations held by the kibbutzim holding Bermad with several investment entities, in order to realize part of their investment in the private company.

Bromed, which owns Evron (75%) and Saar, operates in the field of manufacturing hydraulic control valves for water transport systems. The solutions offered by Bermad combine advanced flow control technologies and are considered leaders in their field. The Company’s products are marketed through subsidiaries to 70 countries around the world. According to the Dun & Bradstreet Industry Companies ‘ranking of 2019, Baramad’s annual turnover is close to NIS 500 million, almost all of it for exports. The company has a shareholders’ equity of about NIS 250,000 and has 700 employees.Kibbutz Mishmar HaEmek controls Tama Plastic Industries, considered one of the three leading companies in the kibbutz industry. As a result Mishmar Ha’emek is considered one of the richest kibbutzim, and in recent years has made investments in various fields in order to diversify its sources of income. The main area of ​​specialization of the Tama plant is packaging and protection products for agriculture, including covers for hay and cotton, nets for various uses, wires and ropes, household utensils and plastic products.According to Dun & Bradstreet, Tama’s annual turnover is NIS 2 billion, almost entirely for export, and its shareholders’ equity is close to NIS 1 billion. The company has over 1,600 employees.

Eladav joins the nonbanking trend: Acquires 25% of Malran, which provides credit to businesses in the Arab sectorEldav will invest NIS 21 million in the shares of Malran, which is controlled by Ryan Mohand, in addition to a loan of NIS 17 million.About six months after separating from its investment in the I-Jump and Trampolines (iJump) complexes(168.7 -0.76%)Are now investing in the growth of non-bank credit, and are interested in issuing this activity later.he company, which is controlled by chairman Ronnie Sternbach, announced today that it has signed an agreement to purchase a 25% stake in private company Mellern, through a private placement, for NIS 21 million, in addition to a loan of NIS 17 million.

According to Eladav, Malaren, which is controlled by Ryan Muend, began operating in 2008, and its activity focuses “especially on providing credit to businesses in the Arab sector (B2B), mainly through the trade in deferred communications.” Trading in deferred messages is a conversion transaction in which the Company’s customers receive the monetary value of their rejected checks, which are transferred to the Company in return for a commission determined in percentagesIn the framework of the investment agreement, Malaren undertook to do so, and Mohand undertook to exercise all of its means of control in Malran, so that Marran will make the best efforts to complete raising debt or capital by way of issuing bonds or shares of Malran quickly As possible. “Loan at an annual interest rate of 6% -7%Eldav notes that the proceeds will be given on two dates: NIS 10 million near the date of signing the deal and NIS 11 million after the publication of Melerne’s financial statements for the first half of the year, on condition that it present NIS 30 million in shareholders’ equity. The amount of the consideration will be granted to Malran as a convertible loan to the allotted shares, and the remainder will bear fixed annual interest of 3.9% and will be repaid in one payment or alternatively converted into shares.In respect of the loan, Hadav states that it will bear fixed annual interest in the range of 6% -7% and will be repaid in one payment (Bullet), two years from the closing date of the transaction or upon the completion of an issue of at least NIS 30 million. Subject to completion of the transaction, which requires the fulfillment of several conditions, including the approvals required of the Ministry of Finance (the Capital Market Authority) and the Ministry of Economy (the Commissioner of Competition).

In addition to deferred transfers, Malran also deals with providing loans to customers for the purpose of financing real estate investments, and provides credit for financing the purchase of tools and heavy equipment, trucks and tools. Customers’ cash, in such a way as to enable them, inter alia, to meet their current obligations in the course of their business. “According to the data presented by Eladav, Malren’s credit portfolio amounts to NIS 300 million, and its revenues for the first quarter of 2019 were NIS 11 million, with a net profit of NIS 2 million, after the entire 2018 agreement with revenues of NIS 45 million And a net profit of NIS 12.5 million10 non-bank credit companies in Tel AviThe non-bank credit field on the Tel Aviv Stock Exchange has grown considerably in recent years, and currently close to 10 traded companies are active in the field.Eldav’s share reacted favorably to the announcement, in a small trading cycle, and altogether a year back, showing a zero return and reflecting a company value of less than NIS 60 million. Its main activity today is the provision of information and data security consulting services through Comsec.

At the end of last January, Eladav announced that it would sell its holdings in I-Jump to its partner, Michael Sabe, at a price similar to the one it entered into, and for less than NIS 4.5 million – about a year and a half after it entered the investment. In March, Eldav completed the deal.The Jellyfish digital advertising agency is acquiring Israeli PerelviewAfter completing the assimilation process, Perelview will become the official Israeli branch of the groupAfter months without a deal to buy an advertising agency, a new deal is finally being made: “Globes” has learned that the Jellyfish digital advertising agency is acquiring the Israeli advertising agency Perelview. After completing the assimilation process, Perelview will become the official Israeli branch of the group.The deal was formed in recent months, after Jellyfish made a decision to enter Israel. In the industry it is estimated that the “best man” for the deal is Google, that Jellyfish’s activity relies mainly on its tools. This assessment is due to the fact that, unlike the usual Jellyfish, they have not examined other alternatives in Israel and devoted themselves to negotiations with Perelview for a long time.

you may like
Scroll Up